-
Ursula A. Matulonis, MD; Dana-Farber Cancer Institute; 5Live; #SGO21
6:44
-
Brian Slomovitz, MD; Broward Health; 5Live; #SGO21
5:37
-
Ramez Eskander, MD; UC San Diego; 5Live; #SGO21
8:45
-
Ritu Salani, MD; University of California, Los Angeles; 5Live; #SGO21
2:57
-
Shannon N. Westin, MD, MPH; UT MD Anderson Cancer Center; 5Live; #SGO21
5:10
-
Michael Birrer, MD, PhD; University of Arkansas; 5Live; #SGO21
9:44
-
Angeles Alvarez Secord, MD, MHSc; Duke Cancer Institute; 5Live; #SGO21
11:18
-
COVID-19: Impact on Caring for Your Patients With Gynecologic Malignancies_Episode 2
58:03
-
"Andres Poveda, MD Initia Oncology Hospital Quironsalud Valencia, Spain 5 Live #ASCO20"
4:57
Key Insights on Olaparib maintenance monotherapy for non-germline BRCA1/2-mutated (non-gBRCAm) platinum-sensitive relapsed ovarian cancer (PSR OC) patients (pts): Phase IIIb OPINION interim analysis.
-
Andres Poveda, MD Initia Oncology Hospital Quironsalud Valencia, Spain 5 Live #ASCO20
4:57
Key Insights on Final overall survival (OS) results from SOLO2/ENGOT-ov21: A phase III trial assessing maintenance olaparib in patients (pts) with platinum-sensitive, relapsed ovarian cancer and a BRCA mutation.
-
Episode 1 - COVID-19: Impact on Caring for Your Patients With Gynecologic Malignancies
54:12
ABOUT
Bio Ascend is an independent medical education company committed to supporting healthcare providers in their efforts to translate innovative science into clinical practice.
The Bio Ascend team has deep oncology and hematology expertise with a proven ability to distill complex scientific ideas into their essential components, as well as extensive experience in planning, executing, and assessing meaningful education for clinicians.
CONNECT
© Copyright 2021 Bio Ascend, a Vaniam Group company